{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:24:07Z","timestamp":1792610647775,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p><jats:italic>Carbapenem-resistant Pseudomonas aeruginosa<\/jats:italic> (<jats:italic>CRPA<\/jats:italic>) infections pose a critical clinical challenge. Although ceftazidime\/avibactam (CAZ\/AVI) and polymyxin B (PMB) are frontline therapies, their comparative effectiveness in terms of 30-day survival, renal safety profiles, and clinical success rates remains poorly characterized. To address this knowledge gap, a multicenter real-world study was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>CRPA<\/jats:italic>-infected patients treated with PMB or CAZ\/AVI-based regimens were enrolled from five hospitals between January 1, 2021, to July 31, 2023. Propensity score matching (PSM) and binary logistic regression analysis were performed to evaluate efficacy and acute renal injury (AKI) occurrence, and a multivariable COX proportional hazards regression of the 30-day all-cause mortality was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>170 <jats:italic>CRPA<\/jats:italic>-infected patients were enrolled, among whom 124 (72.9%) had d<jats:italic>ifficult-to-treat resistant P. aeruginosa (DTR-PA)<\/jats:italic> infections and 77 (45.3%) received CAZ\/AVI-based regimens. After 1:1 PSM, the results demonstrated that the <jats:italic>CRPA<\/jats:italic> clearance rate was significantly higher in the CAZ\/AVI group compared to the PMB group (61.0% vs. 24.4%, <jats:italic>p<\/jats:italic> = 0.001); however, no significant differences were observed in clinical success rates (55.6% vs. 44.4%), incidence of AKI (26.8% vs. 39.0%), or 30-day all-cause mortality (7.3% vs. 12.2%) between the two groups (all <jats:italic>p<\/jats:italic> &amp;gt; 0.05). Compared with the PMB-based regimens, CAZ\/AVI-based regimens were significantly associated with <jats:italic>CRPA<\/jats:italic> clearance success (OR 0.185, 95%CI 0.061\u20130.564, <jats:italic>p<\/jats:italic> &amp;lt; 0.001); additionally, multi-site infection (OR 0.295, 95%CI 0.097\u20130.899, <jats:italic>p<\/jats:italic> = 0.032) and the number of combined anti-<jats:italic>PA<\/jats:italic> antibiotics (OR 0.435, 95%CI 0.213\u20130.888, <jats:italic>p<\/jats:italic> = 0.022) were associated with enhanced <jats:italic>CRPA<\/jats:italic> clearance. The occurrence of AKI in patients with <jats:italic>CRPA<\/jats:italic> infection was associated with underlying diseases, including sepsis\/septic shock (OR 3.405, 95%CI 1.007\u201311.520, <jats:italic>p<\/jats:italic> = 0.049), and diabetes mellitus (OR 3.600, 95%CI 1.018\u201312.733, <jats:italic>p<\/jats:italic> = 0.047). In addition, other <jats:italic>CREs<\/jats:italic> infection (HR 40.849, 95%CI 3.323\u2013502.170, <jats:italic>p<\/jats:italic> = 0.004), APACHE II score (HR 1.072, 95%CI 1.032\u20131.114, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) were found to be independent predictors of 30-day all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, CAZ\/AVI-based regimens demonstrated superior efficacy in clearing <jats:italic>CRPA<\/jats:italic> compared to PMB-based regimens. Furthermore, several factors associated with AKI and mortality in <jats:italic>CRPA<\/jats:italic>-infected patients were identified, highlighting the need for further research to optimize treatment strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1533952","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:48:21Z","timestamp":1743403701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["The efficacy and safety of ceftazidime\/avibactam or polymyxin B based regimens for carbapenem-resistant Pseudomonas aeruginosa infection: a multicenter real-world and propensity score-matched study"],"prefix":"10.3389","volume":"16","author":[{"given":"Wen-Ming","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1186\/s12879-020-05534-1","article-title":"Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia","volume":"20","author":"Alonso","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s10096-017-3039-z","article-title":"The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs","volume":"36","author":"Borgatta","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijid.2022.01.055","article-title":"Risk factors for polymyxin B-associated acute kidney injury","volume":"117","author":"Chang","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s15010-023-02108-6","article-title":"Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis","volume":"52","author":"Chen","year":"2024","journal-title":"Infection"},{"key":"B6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect. Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/QCO.0000000000000966","article-title":"MDR\/XDR\/PDR or DTR? Which definition best fits the resistance profile of Pseudomonas aeruginosa?","volume":"36","author":"Cosentino","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.2147\/DDDT.S309825","article-title":"Evaluation of ceftazidime\/avibactam administration in enterobacteriaceae and Pseudomonas aeruginosa bloodstream infections by Monte Carlo simulation","volume":"15","author":"Dai","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e02187","DOI":"10.1128\/AAC.02187-18","article-title":"Dose selection and validation for ceftazidime-avibactam in adults with complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia","volume":"63","author":"Das","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2147\/IDR.S495240","article-title":"Risk factors for development and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in a Chinese teaching hospital: a seven-year retrospective study","volume":"18","author":"Dong","year":"2025","journal-title":"Infect. Drug Resist"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jceh.2022.04.016","article-title":"Ceftazidime-avibactam for the treatment of carbapenem-resistant Klebsiella pneumoniae infections in patients with liver cirrhosis","volume":"12","author":"Feldman","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ijp.ijp_1013_20","article-title":"Effect of combined colistin and meropenem against meropenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa by checkerboard method: a cross sectional analytical study","volume":"53","author":"Gunalan","year":"2021","journal-title":"Indian J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jac\/dkab461","article-title":"Prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa and association with clinical outcomes in patients: an observational study","volume":"77","author":"Howard-Anderson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jgar.2021.07.020","article-title":"Pharmacokinetic\/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime\/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China","volume":"27","author":"Kang","year":"2021","journal-title":"J. Glob. Antimicrob. Resist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","article-title":"Acute kidney injury","volume":"7","author":"Kellum","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13613-022-01033-5","article-title":"Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study","volume":"12","author":"Liu","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/14787210.2022.2020099","article-title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","volume":"20","author":"Lodise","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3760\/cma.j.cn112147-20220407-00290","article-title":"Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults","volume":"45","author":"Pulmonary","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3760\/cma.j.cn112147-20220407-00290","article-title":"Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults","volume":"45","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"909731","DOI":"10.3389\/fcimb.2022.909731","article-title":"What is new in the anti-Pseudomonas aeruginosa clinical development pipeline since the 2017 WHO alert?","volume":"12","author":"Reig","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1222044","DOI":"10.3389\/fphar.2023.1222044","article-title":"Use of polymyxin B with different administration methods in the critically ill patients with ventilation associated pneumonia: a single-center experience","volume":"14","author":"Shi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1329307","DOI":"10.3389\/fphar.2024.1329307","article-title":"Ceftazidime-avibactam induced renal disorders: past and present","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/phar.2338","article-title":"Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration","volume":"39","author":"Soukup","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"780991","DOI":"10.3389\/fphar.2022.780991","article-title":"Therapeutic drug monitoring of ceftazidime-avibactam concentrations in carbapenem-resistant K. Pneumoniae-infected patients with different kidney statuses","volume":"13","author":"Teng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0146822","DOI":"10.1128\/spectrum.01468-22","article-title":"The efficacy of colistin combined with amikacin or levofloxacin against Pseudomonas aeruginosa biofilm infection","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","article-title":"Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis","volume":"14","author":"Wang","year":"2025","journal-title":"Antimicrob. Resist Infect. Control"},{"key":"B31","unstructured":"WHO bacterial priority pathogens list, 2024\n          \n          \n          2024"},{"key":"B32","doi-asserted-by":"publisher","first-page":"672543","DOI":"10.3389\/fphar.2022.672543","article-title":"Polymyxin B-associated nephrotoxicity and its predictors: a retrospective study in carbapenem-resistant gram-negative bacterial infections","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"107021","DOI":"10.1016\/j.ijantimicag.2023.107021","article-title":"Clinical efficacy of ceftazidime\/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa","volume":"63","author":"Xu","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1137811","DOI":"10.3389\/fmicb.2023.1137811","article-title":"Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3201\/eid2910.230509","article-title":"Pseudomonas aeruginosa high-risk sequence type 463 Co-producing KPC-2 and AFM-1 carbapenemases, China, 2020-2022","volume":"29","author":"Zhang","year":"2023","journal-title":"Emerg. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1533952\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T06:48:26Z","timestamp":1743403706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1533952\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1533952"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1533952","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"article-number":"1533952"}}